X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Nurix currently intends to use the net proceeds to fund clinical development of its drug candidates, including NX-5948, an investigational, orally bioavailable, small molecule degrader of BTK, for the treatment of B-cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan
Deal Size: $188.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 16, 2024
Details:
Nurix currently intends to use the net proceeds to fund clinical development of its drug candidates, including NX-5948, an investigational, orally bioavailable, small molecule degrader of BTK, for the treatment of B-cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities
Deal Size: $175.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2024
Details:
NX-5948 is an orally available, selective degrader of Bruton’s tyrosine kinase. Currently, it is being evaluated with patients for the treatment of B cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. It is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK. NX-5948 has been designed to lack cereblon immunomodulatory activity for potential applications in indications where sparing immunomodulatory activity may be beneficial.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2022
Details:
NX-5948 is an investigational, orally bioavailable, small molecule degrader of BTK that, unlike NX-2127, has been designed to lack cereblon immunomodulatory activity for potential applications in indications where sparing immunomodulatory activity may be beneficial.
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
NX-5948 was able to cross the blood brain barrier in preclinical models, degrade BTK in both microglia and central nervous system (CNS) resident lymphoma cells, and exert anti-lymphoma activity in a model of primary central nervous system lymphoma (PCNSL).
Lead Product(s): NX-5948
Therapeutic Area: Oncology Product Name: NX-5948
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
